Currently, several types of immunotherapy (IT) have been studied for its efficacy in treating hepatocellular carcinoma, such as atezolizumab and bevacizumab, which work as inhibitors in checkpoints and inhibitors in VEGF, respectively. Here, VEGFA is linked to hepatocellular carcinoma.